Published in PLoS One on March 18, 2015
Age- and Brain Region-Specific Changes of Glucose Metabolic Disorder, Learning, and Memory Dysfunction in Early Alzheimer's Disease Assessed in APP/PS1 Transgenic Mice Using (18)F-FDG-PET. Int J Mol Sci (2016) 0.77
A semi-mechanism approach based on MRI and proteomics for prediction of conversion from mild cognitive impairment to Alzheimer's disease. Sci Rep (2016) 0.75
Multidirectional inhibition of cortico-hippocampal neurodegeneration by kolaviron treatment in rats. Metab Brain Dis (2017) 0.75
Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology (1984) 119.59
Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem (2002) 35.30
Mild cognitive impairment as a diagnostic entity. J Intern Med (2004) 26.95
Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res (1987) 10.80
Exponentially modified protein abundance index (emPAI) for estimation of absolute protein amount in proteomics by the number of sequenced peptides per protein. Mol Cell Proteomics (2005) 10.67
Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol (1999) 10.45
Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci U S A (2004) 5.65
Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry (2010) 3.64
Scaffold: a bioinformatic tool for validating MS/MS-based proteomic studies. Proteomics (2010) 2.96
Complement activation by beta-amyloid in Alzheimer disease. Proc Natl Acad Sci U S A (1992) 2.84
Spatial correlation between brain aerobic glycolysis and amyloid-β (Aβ ) deposition. Proc Natl Acad Sci U S A (2010) 2.80
An improved cycling assay for nicotinamide adenine dinucleotide. Anal Biochem (1973) 2.60
Alzheimer's disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons. Proc Natl Acad Sci U S A (2008) 2.59
Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch Neurol (2002) 2.58
High-resolution respirometry: OXPHOS protocols for human cells and permeabilized fibers from small biopsies of human muscle. Methods Mol Biol (2012) 2.49
Plasma clusterin and the risk of Alzheimer disease. JAMA (2011) 2.19
ERM proteins: head-to-tail regulation of actin-plasma membrane interaction. Trends Biochem Sci (1997) 2.12
Plasma concentrations of vitamins A and E and carotenoids in Alzheimer's disease. Age Ageing (1992) 2.12
Microvascular injury and blood-brain barrier leakage in Alzheimer's disease. Neurobiol Aging (2006) 2.03
Proteome-based plasma biomarkers for Alzheimer's disease. Brain (2006) 1.98
Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease. J Exp Med (2007) 1.91
The nexus of chromatin regulation and intermediary metabolism. Nature (2013) 1.87
Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death. Neurobiol Aging (2002) 1.86
Plasma proteins predict conversion to dementia from prodromal disease. Alzheimers Dement (2014) 1.85
Increased 8,12-iso-iPF2alpha-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann Neurol (2000) 1.79
Energy inhibition elevates beta-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: possible early events in Alzheimer's disease pathogenesis. J Neurosci (2005) 1.76
Regional distribution of neurofibrillary tangles and senile plaques in the cerebral cortex of elderly patients: a quantitative evaluation of a one-year autopsy population from a geriatric hospital. Cereb Cortex (1994) 1.73
Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Brain Res Mol Brain Res (2003) 1.70
Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease. J Immunol (2009) 1.66
Up-regulated production and activation of the complement system in Alzheimer's disease brain. Am J Pathol (1999) 1.60
Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects. Neurol Res (2006) 1.56
Fibrinogen is associated with an increased risk of Alzheimer disease and vascular dementia. Stroke (2005) 1.42
Early detection of Alzheimer's disease using neuroimaging. Exp Gerontol (2006) 1.41
Neuroinflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer's disease. Arch Med Res (2007) 1.41
Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients. Neuroreport (2002) 1.35
Expression of heat shock proteins in Alzheimer's disease. Neurology (1991) 1.35
The Sydney Memory and Ageing Study (MAS): methodology and baseline medical and neuropsychiatric characteristics of an elderly epidemiological non-demented cohort of Australians aged 70-90 years. Int Psychogeriatr (2010) 1.32
Complement biosynthesis in the central nervous system. Crit Rev Oral Biol Med (1995) 1.31
Mining biomarkers in human sera using proteomic tools. Proteomics (2004) 1.30
Candidate blood proteome markers of Alzheimer's disease onset and progression: a systematic review and replication study. J Alzheimers Dis (2014) 1.29
Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people. JAMA Neurol (2013) 1.29
Spontaneous classical pathway activation and deficiency of membrane regulators render human neurons susceptible to complement lysis. Am J Pathol (2000) 1.27
Human microglial cells: characterization in cerebral tissue and in primary culture, and study of their susceptibility to HIV-1 infection. Ann Neurol (1991) 1.26
Fueling the flame: bioenergy couples metabolism and inflammation. J Leukoc Biol (2012) 1.26
Increased oxidative stress in Alzheimer's disease as assessed with 4-hydroxynonenal but not malondialdehyde. QJM (2001) 1.24
Thrombin and inflammatory proteins are elevated in Alzheimer's disease microvessels: implications for disease pathogenesis. J Alzheimers Dis (2006) 1.24
Neuronal expression of mRNAs for complement proteins of the classical pathway in Alzheimer brain. Brain Res (1997) 1.24
Complement activation by neurofibrillary tangles in Alzheimer's disease. Neurosci Lett (2001) 1.20
Proteome-based identification of plasma proteins associated with hippocampal metabolism in early Alzheimer's disease. J Neurol (2008) 1.11
Blood-brain barrier permeability in Alzheimer's disease: a case-control MRI study. Psychiatry Res (2009) 1.10
Thrombin and prothrombin are expressed by neurons and glial cells and accumulate in neurofibrillary tangles in Alzheimer disease brain. J Neuropathol Exp Neurol (2006) 1.09
Abeta and human amylin share a common toxicity pathway via mitochondrial dysfunction. Proteomics (2010) 1.08
Yin and Yang: complement activation and regulation in Alzheimer's disease. Prog Neurobiol (2003) 1.08
Protein disulfide isomerases in neurodegeneration: from disease mechanisms to biomedical applications. FEBS Lett (2012) 1.07
Neuroinflammation in the pathogenesis of Alzheimer's disease. A rational framework for the search of novel therapeutic approaches. Front Cell Neurosci (2014) 1.06
Plasma biomarkers of brain atrophy in Alzheimer's disease. PLoS One (2011) 1.06
Deficiency of complement defense protein CD59 may contribute to neurodegeneration in Alzheimer's disease. J Neurosci (2000) 1.05
The actin-binding ERM protein Moesin binds to and stabilizes microtubules at the cell cortex. J Cell Biol (2013) 1.04
Synaptic mitochondrial pathology in Alzheimer's disease. Antioxid Redox Signal (2011) 1.04
Titers of nine complement components, conglutinin and C3b-inactivator in adult and fetal bovine sera. Mol Immunol (1980) 1.01
No diagnostic value of plasma clusterin in Alzheimer's disease. PLoS One (2012) 1.01
Human serum from patients with septic shock activates transcription factors STAT1, IRF1, and NF-kappaB and induces apoptosis in human cardiac myocytes. J Biol Chem (2005) 1.00
Comparison of chemosensitivity tests: clonogenic assay versus MTT assay. Acta Med Okayama (2002) 0.99
Oxidative modification of proteins in the frontal cortex of Alzheimer's disease brain. Neurobiol Aging (2005) 0.99
Detection of the membrane inhibitor of reactive lysis (CD59) in diseased neurons of Alzheimer brain. Brain Res (1991) 0.98
Thrombin accumulation in brains of patients with Alzheimer's disease. Neurosci Lett (1992) 0.98
Activities of key glycolytic enzymes in the brains of patients with Alzheimer's disease. J Neural Transm (Vienna) (1999) 0.98
C4b-binding protein in Alzheimer's disease: binding to Abeta1-42 and to dead cells. Mol Immunol (2008) 0.97
Protein quality control in neurodegenerative disease. Prog Mol Biol Transl Sci (2012) 0.97
Adaptation of microplate-based respirometry for hippocampal slices and analysis of respiratory capacity. J Neurosci Res (2011) 0.97
Inflammatory response of microglial BV-2 cells includes a glycolytic shift and is modulated by mitochondrial glucose-regulated protein 75/mortalin. FEBS Lett (2013) 0.95
Cerebral amyloid angiopathy in a 95+ cohort: complement activation and apolipoprotein E (ApoE) genotype. Neuropathol Appl Neurobiol (2005) 0.95
Synthetic Alzheimer amyloid beta/A4 peptides enhance production of complement C3 component by cultured microglial cells. Brain Res (1993) 0.95
Aberrant profiles of native and oxidized glycoproteins in Alzheimer plasma. Proteomics (2003) 0.94
The neurobiology of isoprostanes and Alzheimer's disease. Biochim Biophys Acta (2010) 0.94
Micro spies from the brain to the periphery: new clues from studies on microRNAs in neuropsychiatric disorders. Front Cell Neurosci (2014) 0.93
Fibrinogen gamma-A chain precursor in CSF: a candidate biomarker for Alzheimer's disease. BMC Neurol (2007) 0.93
Plasma gelsolin is decreased and correlates with rate of decline in Alzheimer's disease. J Alzheimers Dis (2010) 0.92
Variance in the identification of microRNAs deregulated in Alzheimer's disease and possible role of lincRNAs in the pathology: the need of larger datasets. Ageing Res Rev (2014) 0.90
Redox proteomics analysis of HNE-modified proteins in Down syndrome brain: clues for understanding the development of Alzheimer disease. Free Radic Biol Med (2014) 0.89
Cerebrospinal fluid protein variations in common to Alzheimer's disease and schizophrenia. Appl Theor Electrophor (1992) 0.88
The discovery and early validation of novel plasma biomarkers in mild-to-moderate Alzheimer's disease patients responding to treatment with rosiglitazone. Biomarkers (2008) 0.87
Cerebral glucose transport and metabolism in preterm human infants. J Cereb Blood Flow Metab (1998) 0.87
Both plasma retinol-binding protein and haptoglobin precursor allele 1 in CSF: candidate biomarkers for the progression of normal to mild cognitive impairment to Alzheimer's disease. Neurosci Lett (2008) 0.86
Heat shock protein (hsx70) mRNA expression in human brain: effects of neurodegenerative disease and agonal state. Neuropathol Appl Neurobiol (1993) 0.86
Decreased expression and increased oxidation of plasma haptoglobin in Alzheimer disease: Insights from redox proteomics. Free Radic Biol Med (2012) 0.85
Metabolic and cellular characterization of immortalized human microglial cells under heat stress. Neurochem Int (1998) 0.84
Plasma protein profiling of Mild Cognitive Impairment and Alzheimer's disease using iTRAQ quantitative proteomics. Proteome Sci (2014) 0.83
Inability of plasma and urine F2A-isoprostane levels to differentiate mild cognitive impairment from Alzheimer's disease. Neurodegener Dis (2010) 0.82
Complement C1 inhibitor is produced by brain tissue and is cleaved in Alzheimer disease. Brain Res (1995) 0.82
Uptake and mitochondrial dysfunction of alpha-synuclein in human astrocytes, cortical neurons and fibroblasts. Transl Neurodegener (2013) 0.81
Is verbal episodic memory in elderly with amyloid deposits preserved through altered neuronal function? Cereb Cortex (2013) 0.81
Parkinsonian serum carries complement-dependent toxicity for rat mesencephalic dopaminergic neurons in culture. Brain Res (1994) 0.81
Complement C8 deficiency with recurrent meningococcemia: examination of meningococcal opsonization. Aust Paediatr J (1985) 0.81
Antibodies to fibronectin bind to plaques and other structures in Alzheimer's disease and control brain. Neurosci Lett (1990) 0.81
Human serum stimulates Alzheimer markers in cultured hippocampal neurons. J Neurosci Res (1992) 0.81
Characterization of mitochondrial dysfunction in the 7PA2 cell model of Alzheimer's disease. J Alzheimers Dis (2013) 0.80
In vitro and in vivo evaluation of various carbonyl compounds against cyanide toxicity with particular reference to alpha-ketoglutaric acid. Drug Chem Toxicol (2008) 0.80
Effect of ammonia on endocytosis and cytokine production by immortalized human microglia and astroglia cells. Neurochem Int (1996) 0.80
Involvement of the kynurenine pathway in the pathogenesis of Parkinson's disease. Prog Neurobiol (2016) 0.79
Rhodiola rosea L. and Alzheimer's Disease: From Farm to Pharmacy. Phytother Res (2016) 0.78
Serum nicotinamide adenine dinucleotide levels through disease course in multiple sclerosis. Brain Res (2013) 0.77
Topoisomerase I inhibition leads to length-dependent gene expression changes in human primary astrocytes. Genom Data (2016) 0.75
Changes in Cathepsin D and Beclin-1 mRNA and protein expression by the excitotoxin quinolinic acid in human astrocytes and neurons. Metab Brain Dis (2014) 0.75
Molecular targets of Tannic Acid in Alzheimer’s disease Curr Alzheimer Res (2017) 0.75
Resveratrol and Alzheimer's Disease: Mechanistic Insights. Mol Neurobiol (2016) 0.75
Age-related neurodegenerative disease associated pathways identified in retinal and vitreous proteome from human glaucoma eyes. Sci Rep (2017) 0.75